Pharmaceuticals, Biotechnology And Diagnostics M&A Agreements Report/Directory 2026: Analyse 2,500+ Deals Signed Since 2021 - Company A-Z, Therapeutic Area, Technology Type, And Industry Segment

(MENAFN- GlobeNewsWire - Nasdaq) Access over 2,500 M&A deals in one consolidated resource, eliminating the need to search multiple databases, press releases, and regulatory filings.

Dublin, March 12, 2026 (GLOBE NEWSWIRE) -- The "Merger and Acquisition (M&A) Deals in Pharmaceuticals, Biotechnology and Diagnostics 2021-2026" report has been added to ResearchAndMarkets's offering.
The Merger and Acquisition (M&A) Deals in Pharmaceuticals, Biotechnology and Diagnostics 2021-2026 report provides a comprehensive analysis of acquisition activity across the global life sciences sector. Designed for corporate development, business development, investment, and strategy professionals, the report delivers detailed insight into how companies structure mergers and acquisitions and negotiate the financial terms behind these transactions.
Fully revised and updated, the report analyzes 2,500+ M&A agreements announced between January 2021 and March 2026, offering an extensive view of acquisition activity across pharmaceutical, biotechnology, and diagnostics companies.
Each transaction links to a detailed online deal record and, where available, the original contract documents filed with regulators. By combining comprehensive deal data, financial benchmarking, and contract access, the report provides valuable intelligence for evaluating acquisition opportunities, benchmarking transaction values, and understanding industry consolidation strategies.
Key Benefits

• Save Significant Research Time: Access over 2,500 M&A deals in one consolidated resource, eliminating the need to search multiple databases, press releases, and regulatory filings.
• Benchmark Acquisition Structures and Valuations: Understand how pharmaceutical, biotechnology, and diagnostics companies structure acquisitions, including cash transactions, equity deals, and hybrid structures.
• Analyze Transaction Values with Confidence: Review disclosed deal values and financial terms to benchmark acquisition prices and transaction structures across comparable deals.
• Access Real Contract Documents: Where available, explore SEC-filed merger and acquisition agreements, providing insight into the detailed contractual provisions behind real transactions.
• Identify the Most Active Acquirers: Discover which companies are leading consolidation activity and analyze their acquisition strategies.
• Track Industry Consolidation Trends: Analyze M&A activity across companies, therapeutic areas, and technology sectors to understand how the life sciences industry is evolving.

What's Included in the Report

• Analysis of M&A dealmaking trends since 2021
• Overview of merger and acquisition transaction structures
• Review of leading acquisitions by disclosed deal value
• Profiles of the most active acquirers and dealmakers
• Detailed analysis of deals by company, therapeutic area, technology type, and industry segment
• A comprehensive directory of M&A transactions announced since 2021
• Links to online deal records and contract documents where available

Due Diligence Insights from Real Agreements

• Asset and company acquisition structures
• Purchase price and payment mechanisms
• Intellectual property transfer provisions
• Earn-out structures and contingent payments
• Operational integration responsibilities
• Transaction closing conditions and termination clauses

Why This Report Matters
Mergers and acquisitions are a critical strategy for pharmaceutical and biotechnology companies seeking to expand pipelines, acquire innovative technologies, and accelerate growth. The life sciences industry experiences significant M&A activity each year as companies pursue strategic acquisitions to strengthen their portfolios and capabilities.
By combining comprehensive acquisition data, transaction benchmarking, and access to real contract documents, this report provides the intelligence needed to evaluate acquisition opportunities, understand industry consolidation trends, and negotiate more effectively.
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in M&A dealmaking
2.1. Introduction
2.2. Difference between merger and acquisition deals
2.3. Trends in M&A deals since 2021
2.3.1. M&A dealmaking by year since 2021
2.3.2. M&A dealmaking by industry sector since 2021
2.3.3. M&A dealmaking by therapy area since 2021
2.3.4. M&A dealmaking by most active company since 2021
2.4. Key M&A trends
2.5. Option to acquire the new acquisition?
2.6. When M&A can be useful
2.7. Attributes of M&A deals
2.7.1. M&A as an alternative to IPO
2.8. Partnering deals with M&A component
2.8.1. Partnering as a precursor to M&A
2.8.2. Equity as part of partnering deal
2.8.3. Conversion of partnership to acquisition
2.8.4. But M&A is not always the route followed
2.9. Big pharma mega mergers - are we at the end of the road?
2.9.1. Growth of Johnson & Johnson through M&A
2.9.2. Growth of Novartis through M&A
2.10. Accessing innovation through M&A
2.10.1. Big pharma acquisitions of small companies
2.10.2. Medium and small biopharma - use of M&A
2.10.3. Using M&A to build a company
2.10.4. Emergence of biotech-biotech mergers
2.11. The emerging role of private equity in M&A
2.12. Implementing M&A transactions
2.13. Joint ventures as alternative to M&A
2.14. The future of M&A in biopharma
Chapter 3 - Overview of M&A deal structure
3.1. Introduction
3.2. Pure versus multi-component acquisition deals
3.3. Pure M&A agreement structure
3.4. Acquisition as part of a wider alliance agreement
3.5. Merger agreements
Chapter 4 - Leading M&A deals
4.1. Introduction
4.2. Top M&A deals by value
Chapter 5 - Top 25 most active M&A dealmakers
5.1. Introduction
5.2. Top 25 most active M&A dealmakers
Chapter 6 - M&A contract directory since 2021
6.1. Introduction
6.2. M&A deals with contracts since 2021
For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN12032026004107003653ID1110853623